Investor
Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 425 (CSE: $BBM.C)
(CSE: $XCX.C) (OTC: $VSYM) (TSX:
$APHA.TO) (NASDAQ: $APHA)
Delta, Kelowna, BC, June 8, 2020 (Investorideas.com Newswire)
www.Investorideas.com, a global news source covering leading sectors including
marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we will be looking at a few public company announcements.
Blueberries Medical
Corp.
(CSE:
BBM)
(OTC:
BBRRF), a Latin American licensed producer of medicinal
cannabis and cannabis-derived products, announced that
its wholly-owned subsidiary Blueberries SAS entered into a collaboration
agreement with Medicanmentos de Cannabis SAS, to develop, and produce
Tetrahydrocannabinol (“THC”)
cannabis extracts for the international market.
Blueberries
will develop a Research and Development project with medcann to produce
commercial THC dominant extracts. The Company will utilize its extraction
capabilities to process the THC dominant cannabis flower cultivated by medcann.
In 2018, medcann became the first and only company to obtain the registration
of psychoactive varieties of cannabis in Colombia.
Both
companies will work together in the manufacturing and commercialization, taking
advantage of market dynamics and the commercial THC quotas to be assigned to
Blueberries.
In
Q1, 2020, Blueberries commissioned its first extraction line at its 2,800 m2
(30,138 sf) state-of-the-art extraction facility located in a modern and secure
industrial park 30 minutes outside of Bogota. The first extraction line is
fully operational, and the newly commissioned equipment has sufficient capacity
to process biomass from Blueberries’ own cultivation operations, its contract
growers, and other associated licensed producers such as medcann.
The
facility uses supercritical CO2 extraction technology to produce the
highest quality cannabis oil and has been designed with the flexibility to also
employ ethanol extraction technologies to match market demand. The current
extraction capacity exceeds the 70,000kg/year of dried flower with the ability
to accommodate significant future expansion with additional extraction lines.
The Blueberries team is heavily focused on establishing a best-in-class
extraction operation with the goal of becoming a leading extraction center in
Latin America and an international supplier of medicinal-grade cannabis oil
extracts, active pharmaceutical ingredients and related products.
The
installed Vitalis extraction line is the first equipment of its kind in
Colombia having stainless-steel compressor and extraction vessels, built to
stringent European Union - Good Manufacturing Practices standards. The
Company’s facility is designed to comply with EU-GMP standards to ensure
standardization and consistency of production. Blueberries is currently
implementing full EU-GMP standards at its extraction facility and expects to
commence the certification process shortly which would permit additional export
potential to international markets.
"We're
excited to partner with medcann. Our team knows that the best results are
delivered when great people come together to collaborate with a common vision.
This is precisely the environment we have with the team at medcann," said
Camilo Villalba, Chief Executive Officer of Blueberries. "We are just
starting. As we continue to develop and introduce unique THC extracts based on
proprietary genetics from medcann in the coming months, we will have fully
leveraged this opportunity to establish a leading position in the cannabis
extracts markets."
medcann
has established its outdoor agricultural operations in the flattest area of
Colombia, the Eastern plains that account for more than 1/3 of the country, a
100% natural and sustainable agroindustry operation with an exceptionally low
cost per gram of dried flower and with the fastest and most cost-efficient
expansion ability. With more than 800 hectares available upon demand developed
through a significant number of small growers, medcann’s operations generate a
positive social impact with sustainable formal employment.
For
medcann, as the leading company in regulatory milestones in Colombia, the
Partnership represents a new advance in the development of the medicinal
cannabis industry. “Each day we become more convinced of the substantial
contribution that the cannabis sector can make to the recovery of the economy
in these times of crisis. This agreement confirms medcann’s regulatory and
agronomic potential as a driver of change of the industry, as companies rely on
complementary expertise as a key input to develop joint products” said Jon
Ruiz, President of medcann.
AMP German Cannabis
Group Inc. (CSE:
XCX)
announced that it
is developing medical brands for a range of cannabis flower strains, extracts
and other novel dosage forms specifically for the German market supplied by
foreign licenced medical cannabis producers.
Licensed producers that have been EU-GMP certified will cultivate
medical cannabis to AMP's brand specifications and quality standards.
First
large imports of AMP's medical cannabis brand are expected to be coming from
Canada
during the fall of 2020 from licenced producers that were EU-GMP certified
prior to COVID-19 pandemic. AMP only enters into supply agreements with
Canadian licenced producers who can supply a minimum of 1,000 kg annually of
AMP branded medical cannabis, shipped on a monthly basis. AMP is in negotiations with several Canadian
licenced producers to begin shipments in the fall of this year.
AMP
is advancing its other signed Canadian producers to be EU-GMP audited during
the fall of 2020 by the Company's German pharmaceutical consultant and
inspected for certification during early 2021 by TLV (the Thuringian State
Office for Consumer Protection) provided international travel restrictions are
normalized. Because of the COVID-19 pandemic, Germany is not conducting inspections
of foreign medical cannabis producers until the end of 2020.
To
meet future demand as the German market grows, AMP is developing long-term
supply sources in Europe for large scale supply of AMP medical cannabis branded
products. The Company believes as the
German market develops, Europe will become an important and significant medical
cannabis supply source. AMP's strategy
is to develop exclusive relationships with large medical cannabis licenced
producers in certain EU countries for AMP medical cannabis branded products for
the German market.
AMP's
non-exclusive distribution agreement (see press release dated 16th
October 2019) with a leading distributor of pharmaceuticals products to more
than 13,000 pharmacies throughout Germany encompasses purchasing AMP medical
cannabis branded products. In addition, under our lead pharmaceutical
distributor's program, AMP will be investing in physician and pharmacist's
education seminars across Germany about medical cannabis. The Company is also
in negotiations with additional pharmaceutical distributors to purchase AMP
medical cannabis branded products as AMP's imports increases this fall.
Dr.
Stefan Feuerstein, Director of AMP, commented: "We had hoped to fulfill
our distribution agreement with our lead pharmaceutical distributor in regards
to imports from the Netherlands this month but we are optimistic that the
Netherlands will resolve its export quota to Germany and increase exports in
the near future. As already mentioned,
we are in advanced negotiations with several foreign cannabis producers who
already have an EU-GMP certification and are expecting to sign at least one
definitive supply agreement within the next four weeks. Beginning this fall, AMP will be selling AMP
branded medical cannabis products imported from Canada into Germany."
Panaxia Labs Israel
Ltd.
(TASE:
PNAX) traded up following their announcement of
strong financial results. Dr. Dadi Segal, CEO of Panaxia Global, said,
"Panaxia started 2020 with a strong quarter boasting expanded operations,
record quarterly revenues, and a shift to gross profit. Concurrently with
increasing the number of patients in Israel, we are on track to initiate export
and commercial sales in Europe later this year. We have reached several
strategic and financial achievements in the first quarter, including progress
in the regulatory registration of our products in Germany and Denmark."
Dr.
Segal continued, "We look forward to receiving the export license to start
exporting to these and other target countries immediately. Even if the export
license is delayed, we believe the completion of the production facility in
Malta will allow us to expand our sales to Europe, as a provisional alternative
until exports from Israel begin."
In
the first quarter of 2020, the Israeli subsidiary, Pharmaceutical company
Panaxia Labs Israel Ltd., the largest manufacturer of medical cannabis products
in Israel, reports record revenues of 12.2 million, an increase of approx. 83%
compared with the revenues in the fourth quarter of 2019, and a 365%-increase
(over X4 times) compared with the revenues in the first quarter of 2019. The
consecutive, 10-quarter revenue growth is attributed to the expansion of the
production, marketing, and home deliveries operations, as well as to the
transition of working under the new Israeli cannabis regulation, which provides
the Panaxia Israel with higher revenues per product unit. During the first
quarter, Panaxia Israel continued to expand its patient base, as well as the
number of products it delivered. The company estimates that the COVID-19
crisis, which started in the last two weeks of the quarter, has helped
reinforce this trend with an additional increase in demand for products and
home deliveries.
During
the quarter, the company announced it had entered a first-of-a-kind
collaboration agreement in the medical cannabis industry, with Neuraxpharm,
Europe's largest CNS therapies company. It covers the commercialization and
distribution of Panaxia's advanced cannabis products in Germany as part of
Neuraxpharm's broad therapy portfolio.
Cash and cash
equivalents, as of March 30, 2020, were 17.6 million,
compared with 14.3 million in cash and cash equivalents as of December 31,
2019. The increase is primarily due to the closing of a 17 million private
placement of ordinary shares and warrants, led by MORE Investment House and
another accredited/institutional investor. The amount is net of a loan repaid
to the parent company.
Subsequent
to the end of the first quarter, in April 2020, the company strengthened its
balance sheet through a total of 12 million in private placements of ordinary
shares and warrants to the company's controlling shareholders and to long-term
investors, including the chair, Mr. Jonathan Kolber, CEO Dr. Dadi Segal, and
Mr. Ran Nussbaum and others.
View Systems,
Inc.’s (OTC:
VSYM), medical marijuana and hemp subsidiary, Sannabis
S.A.S. released
information on their Work from Home program designed to capture the recently
out of work professionals with the skills to build a business in a nascent
industry. Sannabis’ Indigenous partners began making cannabis-based products
since 2014 under the Sannabis brand. These products have anecdotal evidence of
being effective for thousands of patients around the world as evidenced by the
hundreds of testimonials the company has received and will be posting online.
Sannabis
assisted in the treatment of adults and children with epilepsy, cancer, skin
ailments, fibromyalgia, and many more diseases that caused despair since
nothing else worked for them, until they were introduced to Sannabis. The
company will now capitalize on the goodwill of their brand.
Sannabis
Business Partners (SBP) will be given an activation code after their first US$
40 purchase and have their personal and bank deposit details registered with
Sannabis. A minimum $40/month purchase is required to maintain their code
active. They simply give their code to their customer to buy direct from
Sannabis’ online store. Once their customers payment is finalized, the SBP gets
a direct transfer from Sannabis, and drop ships the products directly to the
customer. As long as SBP maintains an active code, they will receive commission
deposits after every purchase by that customer.
Sannabis
Business Partners (SBP) will be given the opportunity to generate income from 5
different avenues of compensation.
-No.
1: Sannabis Business Partners earn a 20% commission for the purchases made by
their customers that buy directly from Sannabis.
-No.2:
SBP earn a 30% commission for the initial purchase made by a new SANNABIS
ASSOCIATE PARTNER (SAP) they activate (must be trained by SBP before
activation).
-No.
3: SBP earn a 10% commission for each purchase made by the customers of their
SANNABIS ASSOCIATE PARTNER referrals.
-No.
4: SBP earn a 20% commission for the purchases made by the SANNABIS ASSOCIATE
ENTREPENUER after the first purchase (activation), that will surely continue
using the products, so they will continue to earn!
-No.
5: SBP will earn a legal renumeration when they refer patients to our Dr.
Sannabis web portal.
“I’m
very happy to be providing an income opportunity to many people currently out
of work,” stated Juan Pablo Guzman, Director of Sannabis S.A.S.
John
Campo, President of View Systems, Inc. added, “our office in Cali is working
hard to activate as many people as soon as possible so they start generating
income for themselves and for the Company.”
Aphria Inc. (TSX:
APHA) (NASDAQ:
APHA), a leading global cannabis company, announced
today will be its first day of trading on The Nasdaq Global
Select Market ("Nasdaq"), as previously communicated on May 26, 2020,
and will continue to be listed under the ticker symbol "APHA." This
transition will not impact the Company's primary listing on the Toronto Stock
Exchange (TSX: APHA).
Investor ideas reminds all listeners to read
our disclaimers and disclosures on the Investorideas.com website and this
podcast is not an endorsement to buy products or services or securities.
Investors are reminded all investment involves risk and possible loss of investment
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Contact Investorideas.com
800
665 0411
